At Advanced Therapies Week 2026, our Chief Technology Officer, Gregg Nyberg, joined a panel of industry leaders to discuss how advanced therapy developers are navigating the path from early-stage process development to commercial manufacturing. The conversation reinforced something we see in nearly every program we support: the hardest part of scaling a cell or gene therapy isn’t any single inflection point. It’s the series of small, often quiet decisions made years earlier that determine whether the next stage is a smooth translation or a costly reinvention.

Your science is ready. The mechanism is well-characterized, the preclinical data is compelling, and the clinical development path is coming into view. The next question — and one of the most consequential you will face — is who to bring alongside you to build the manufacturing and development infrastructure that gets your therapy to patients.

Extracellular vesicles have been a subject of scientific fascination for decades. For most of that time, they were studied primarily as mediators of intercellular communication – natural couriers shuttling proteins, nucleic acids, lipids, and metabolites between cells. What has shifted dramatically in recent years is the recognition that this biology can be harnessed therapeutically: EVs can be engineered, loaded, scaled, and delivered as a drug product.

Landmark Bio, an Artis BioSolutions company dedicated to accelerating the translation of next-generation advanced therapies from discovery to clinical and commercial production, today announced that it has secured an Advanced Research Projects Agency for Health (ARPA-H) award totaling up to $18.3 million to build an efficient, robust, and scalable continuous manufacturing platform for extracellular vesicles (EVs).

Landmark Bio, an Artis BioSolutions company dedicated to accelerating the translation of next-generation advanced therapies from discovery to clinical and commercial production, today announced that it has secured an Advanced Research Projects Agency for Health (ARPA-H) award totaling up to $18.3 million to build an efficient, robust, and scalable continuous manufacturing platform for extracellular vesicles (EVs).

Artis BioSolutions (“Artis”), a San Diego-based advanced-therapies development and manufacturing company, today announced that it has entered into a definitive agreement to acquire Syngoi Technologies (“Syngoi”), a Spanish biotechnology company pioneering novel enzymatic approaches for manufacturing synthetic DNA technologies.